Almac Expands Commercial API Manufacturing

Almac is expanding its manufacturing capacity to more 30m3 at its European headquarters in Craigavon, UK. The upgraded facility will include reactor vessels with clean room product isolation and drying equipment to allow Highly Potent API manufacture up to 600kg batch size.

Denis Geffroy, vice president of business development, said,  “We are delighted with the progress made over the past two years to increase our presence in late phase clinical development. This capacity increase will allow a smooth transition from late phase clinical development to full commercialization. Scale was becoming a limiting factor for some of our client projects and this new capacity is a strong commitment to offer project continuity. It opens up a new chapter in Almac’s API manufacturing capability”

The facility is expected to be built and validated within the next two years. Almac will continue progressing late stage manufacturing projects within its existing facilities and with a number of key supplier relationships. Dr. Rick Dyer, vice president of operations added, “This expansion allows us to build on our expertise in early phase clinical development projects and further continue our success within late phase projects so clients need not transfer some of our well developed processes elsewhere due to lack of scale. This investment will further place Almac as the supplier of choice to satisfy all client requirements from preclinical phase to full commercialization.”